Neuren's Royalties From Daybue Sales Beat Bull's Forecast -- Market Talk

Dow Jones

Yesterday

2308 ET - Royalty revenue flowing to Neuren Pharmaceuticals from U.S. sales of the Daybue treatment for Rett Syndrome last year beat Macquarie's expectations. Acadia Pharmaceuticals, Neuren's partner, said U.S. net sales of Daybue totaled US$391 million in 2025. That was above the US$350 million of sales achieved in 2024. Macquarie says the sales outcome translates to A$65.0 million in royalties for Neuren, up 15% on year. This is 1.5% higher than its forecast of A$64.0 million. "Royalty revenue ahead of expectations, driven by growth in new patient prescriptions," Macquarie says. "Neuren's strong cash position enables pipeline acceleration, potentially providing significant long-term upside." It has an outperform call on Neuren. (david.winning@wsj.com; @dwinningWSJ)

(END) Dow Jones Newswires

March 03, 2026 18:08 ET (23:08 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2616137072"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2616137072\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2616137072?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-04 07:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2616137072","market":"us","top_or_hot":-1,"title":"Neuren's Royalties From Daybue Sales Beat Bull's Forecast -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     2308 ET - Royalty revenue flowing to <a href=\"https://laohu8.com/S/NEU.AU\">Neuren Pharmaceuticals</a> from U.S. sales of the Daybue treatment for Rett Syndrome last year beat <a href=\"https://laohu8.com/S/MQG.AU\">Macquarie</a>'s expectations. Acadia Pharmaceuticals, Neuren's partner, said U.S. net sales of Daybue totaled US$391 million in 2025. That was above the US$350 million of sales achieved in 2024. Macquarie says the sales outcome translates to A$65.0 million in royalties for Neuren, up 15% on year. This is 1.5% higher than its forecast of A$64.0 million. \"Royalty revenue ahead of expectations, driven by growth in new patient prescriptions,\" Macquarie says. \"Neuren's strong cash position enables pipeline acceleration, potentially providing significant long-term upside.\" It has an outperform call on Neuren. (david.winning@wsj.com; @dwinningWSJ) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 03, 2026 18:08 ET (23:08 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Neuren's Royalties From Daybue Sales Beat Bull's Forecast -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNeuren's Royalties From Daybue Sales Beat Bull's Forecast -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-03-04 07:08</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     2308 ET - Royalty revenue flowing to <a href=\"https://laohu8.com/S/NEU.AU\">Neuren Pharmaceuticals</a> from U.S. sales of the Daybue treatment for Rett Syndrome last year beat <a href=\"https://laohu8.com/S/MQG.AU\">Macquarie</a>'s expectations. Acadia Pharmaceuticals, Neuren's partner, said U.S. net sales of Daybue totaled US$391 million in 2025. That was above the US$350 million of sales achieved in 2024. Macquarie says the sales outcome translates to A$65.0 million in royalties for Neuren, up 15% on year. This is 1.5% higher than its forecast of A$64.0 million. \"Royalty revenue ahead of expectations, driven by growth in new patient prescriptions,\" Macquarie says. \"Neuren's strong cash position enables pipeline acceleration, potentially providing significant long-term upside.\" It has an outperform call on Neuren. (david.winning@wsj.com; @dwinningWSJ) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 03, 2026 18:08 ET (23:08 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7508","symbol_name":"医药生物股","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2616137072","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2616137072","pubTimestamp":1772579280,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"2308 ET - Royalty revenue flowing to Neuren Pharmaceuticals from U.S. sales of the Daybue treatment for Rett Syndrome last year beat Macquarie's expectations. Acadia Pharmaceuticals, Neuren's partner, said U.S. net sales of Daybue totaled US$391 million in 2025. That was above the US$350 million of sales achieved in 2024. Macquarie says the sales outcome translates to A$65.0 million in royalties for Neuren, up 15% on year. This is 1.5% higher than its forecast of A$64.0 million. \"Royalty revenue ahead of expectations, driven by growth in new patient prescriptions,\" Macquarie says. \"Neuren's strong cash position enables pipeline acceleration, potentially providing significant long-term upside.\" It has an outperform call on Neuren. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7508":"医药生物股","NEU.AU":"NEUREN PHARMACEUTICALS LTD","BK7096":"制药"},"translate_title":"Neuren从Daybue销售中获得的特许权使用费超出了公牛的预期——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NEU.AU":0.9},"content_text":"2308 ET - Royalty revenue flowing to Neuren Pharmaceuticals from U.S. sales of the Daybue treatment for Rett Syndrome last year beat Macquarie's expectations. Acadia Pharmaceuticals, Neuren's partner, said U.S. net sales of Daybue totaled US$391 million in 2025. That was above the US$350 million of sales achieved in 2024. Macquarie says the sales outcome translates to A$65.0 million in royalties for Neuren, up 15% on year. This is 1.5% higher than its forecast of A$64.0 million. \"Royalty revenue ahead of expectations, driven by growth in new patient prescriptions,\" Macquarie says. \"Neuren's strong cash position enables pipeline acceleration, potentially providing significant long-term upside.\" It has an outperform call on Neuren. (david.winning@wsj.com; @dwinningWSJ) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 03, 2026 18:08 ET (23:08 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}